Shilanski & Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.79M | Sell |
20,429
-573
| -3% | -$106K | 1.08% | 29 |
|
|
2025
Q1 | $4.4M | Sell |
21,002
-1,563
| -7% | -$327K | 1.37% | 25 |
|
|
2024
Q4 | $4.01M | Buy |
22,565
+386
| +2% | +$68.6K | 1.29% | 27 |
|
|
2024
Q3 | $4.38M | Sell |
22,179
-460
| -2% | -$90.8K | 1.42% | 26 |
|
|
2024
Q2 | $3.88M | Buy |
22,639
+298
| +1% | +$51.1K | 1.31% | 27 |
|
|
2024
Q1 | $4.07M | Buy |
22,341
+156
| +0.7% | +$28.4K | 1.4% | 25 |
|
|
2023
Q4 | $3.44M | Buy |
22,185
+103
| +0.5% | +$16K | 1.31% | 27 |
|
|
2023
Q3 | $3.29M | Buy |
22,082
+347
| +2% | +$51.7K | 1.34% | 27 |
|
|
2023
Q2 | $2.93M | Buy |
21,735
+631
| +3% | +$85K | 1.18% | 31 |
|
|
2023
Q1 | $3.39M | Buy |
21,104
+212
| +1% | +$34.1K | 1.53% | 26 |
|
|
2022
Q4 | $3.38M | Buy |
20,892
+18,449
| +755% | +$2.98M | 1.48% | 26 |
|
|
2022
Q3 | $328K | Sell |
2,443
-18,675
| -88% | -$2.51M | 0.12% | 91 |
|
|
2022
Q2 | $3.23M | Buy |
21,118
+314
| +2% | +$48.1K | 1.51% | 25 |
|
|
2022
Q1 | $3.37M | Sell |
20,804
-402
| -2% | -$65.2K | 1.42% | 26 |
|
|
2021
Q4 | $2.87M | Sell |
21,206
-264
| -1% | -$35.7K | 1.22% | 34 |
|
|
2021
Q3 | $2.32M | Buy |
21,470
+416
| +2% | +$44.9K | 1.08% | 37 |
|
|
2021
Q2 | $2.37M | Buy |
21,054
+454
| +2% | +$51.1K | 1.13% | 35 |
|
|
2021
Q1 | $2.23M | Buy |
20,600
+1
| +0% | +$108 | 1.19% | 35 |
|
|
2020
Q4 | $2.21M | Buy |
+20,599
| New | +$2.21M | 1.34% | 30 |
|